(Total Views: 759)
Posted On: 03/07/2017 12:08:42 PM
Post# of 72447
Just speculating for a moment.
On 2/27 in the shareholder letter,Leo stated they were on track to releasing interim efficacy data for B-UP that week.
Then on Friday,3/3 Leo said " Also, efficacy data from the 2nd cohort in the Brilacidin-Ulcerative Colitis proof-of-concept study is in the last stage of being compiled by the CRO and, following a final review, will be released."
Now I'm not saying that a CDA holder requested the release delay but if that did occur,Leo would not have been able to announce that.
He would not be able to say "A BP with a CDA agreement has asked us not to release anything yet".
So how to explain the delay??? By saying what he said in the 3/3 shareholder letter.
The "on track" statement made on 2/27 might have been meant more for BP than for the shareholders.If the data is that excellent,it may have put BP into a sense of urgency to offer a deal before the competition finds out.
OR.......It could be just a delay.
Kelt
On 2/27 in the shareholder letter,Leo stated they were on track to releasing interim efficacy data for B-UP that week.
Then on Friday,3/3 Leo said " Also, efficacy data from the 2nd cohort in the Brilacidin-Ulcerative Colitis proof-of-concept study is in the last stage of being compiled by the CRO and, following a final review, will be released."
Now I'm not saying that a CDA holder requested the release delay but if that did occur,Leo would not have been able to announce that.
He would not be able to say "A BP with a CDA agreement has asked us not to release anything yet".
So how to explain the delay??? By saying what he said in the 3/3 shareholder letter.
The "on track" statement made on 2/27 might have been meant more for BP than for the shareholders.If the data is that excellent,it may have put BP into a sense of urgency to offer a deal before the competition finds out.
OR.......It could be just a delay.
Kelt
(2)
(0)
